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S U M M A R Y
In 2007, nearly 7000 new cases of HIV infection occurred each day. There is a constant increase in
the proportion of women newly infected with HIV in the global population; this increase is
particularly high in some areas of the world such as sub-Saharan Africa. Microbicides are products
that are being developed to empower women against HIV. First- and second-generation microbicides
are broad-spectrum products that include surface active agents, vaginal defense enhancers,
and blocking agents. Third-generation microbicides are HIV-speciﬁc and include replication and
entry inhibitors formulated as gels or as vaginal rings. However, there is a concern that
antiretroviral-based microbicides could lead to drug resistance if they are used by HIV-positive
women who are unaware of their HIV status. To reach the highest number of women possible,
microbicides should be available over-the-counter, which might not be the case with antiretroviral-
based formulations. In contrast, non-antiretroviral-based microbicides will have the advantage of
being initiated and controlled by women themselves and they will not jeopardize the use of life-
saving drugs.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In 2007, 33 million people were living with HIV/AIDS
worldwide, 67% of whom were in Africa.1 Since the mid-
1990 s, women have represented half of all adults living with
HIV/AIDS.2 In sub-Saharan Africa, three times more 15- to 24-
year-old women than men of the same age are now infected
with HIV. Women, and especially adolescents and younger
women, are biologically more susceptible to HIV infection than
men.3 In addition, infection in women is driven by social,
cultural, and economic gender inequalities that limit their
ability to protect themselves from infection.4,5 Condoms, when
used correctly and consistently, provide a high level of
protection against HIV,6 but many women lack the social and/
or economic power to persuade their partners to use them. To
confront the vulnerability of women and to empower them
against HIV/AIDS, the scientiﬁc community and advocacy groups
have promoted the development of microbicides.7 Microbicides
are products that women can initiate and control to protect
themselves against HIV.8 They can be developed in any form
that is convenient to use such as gel, cream, foam, ﬁlm,
suppository, or vaginal ring.* Corresponding author. Tel.: +1 418 654 2705; fax: +1 418 654 2715.
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First- and second-generation microbicides tend to be broad-
spectrum products that disrupt the viral envelope, maintain
vaginal pH, and/or bind to the virus to inhibit entry. More recently,
pharmaceutical companies have granted royalty-free licenses to
develop, manufacture, and distribute some antiretrovirals (ARVs)
as microbicides in resource-poor countries.9 These third-genera-
tion microbicides may have implications regarding the emergence
of drug-resistant HIV. Indeed, ARVs administered vaginally could
be absorbed systemically and may select for resistance if used by
HIV-positive women who are unaware of their HIV status.10
Therefore, women using ARV-based microbicides should be
monitored for HIV, leading to increased costs and reduced
accessibility to these products, especially if in the future the Food
and Drug Administration (FDA) or other health authorities require
that they be prescribed. We believe that non-ARV-based micro-
bicides available over-the-counter, for women to initiate and
control by themselves, still need to be developed as a novel
prevention technology to curb the number of new HIV infections,
especially in low- and middle-income countries.
Preclinical and clinical research on the most advanced micro-
bicides currently in the pipeline have been extensively reviewed in
several papers.11–18 Brieﬂy, ﬁrst- and second-generation micro-
bicides include surface active agents (e.g., nonoxynol-9 and C31G),
vaginal defenseenhancers (e.g., BufferGel), andblocking agents (e.g.,ses. Published by Elsevier Ltd. All rights reserved.
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their effect on HIV, they may be effective against other sexually
transmitted pathogens. Some of these products may also demon-
strate a contraceptive efﬁcacy, while others may not. Most phase I
and phase II clinical trials completed to date have found these
products to be safe andwell-tolerated.However, phase III trialswith
nonoxynol-9 and cellulose sulfate have shown that they could be
harmful to the vaginal mucosa and increased the risk of HIV
acquisition in women.19–21 Phase III trials with Carraguard1 and
BufferGel have not demonstrated efﬁcacy in preventing HIV
transmission.22,23 Moreover, two phase III trials with C31G did
not produce meaningful results due to lower-than-expected HIV
incidence in the study populations.24,25 More interestingly, a phase
II/IIB trial with PRO 2000/5 gel (a naphthalene sulfonate polymer)
involving 3099 participants showed that it might have some
effectiveness for the prevention of HIV infection.23 Women in the
PRO 2000/5 gel armhad a 30% lower rate of HIV infection compared
with those in the no gel at all, universal placebo gel, and BufferGel
arms, but this effect was not statistically signiﬁcant. Unfortunately,
the phase III clinical trial with PRO 2000/5 gel which involved a
larger number ofwomen (9395) foundnoevidence that this product
reduced the risk of HIV infection.
Other promising ﬁrst- and second-generation microbicides
that are at an earlier stage of preclinical and clinical investigation
include the Invisible Condom1 (a physical/chemical barrier;
phase II/III planned),26,27 praneem polyherbal vaginal tablet
(unknownmechanismof action; phase II completed),28 VivaGel (a
dendrimer-based entry inhibitor; phase I/II ongoing),29,30 ACID-
FORM (a buffering agent; phase I ongoing),31 and SAMMA (a
mandelic acid condensation polymer; in preclinical studies).32
Bioengineered lactobacilli are also being developed to express
proteins (such as CD4,33 a derivative of gp41,34 or cyanovirin35)
that bind to HIV and block either viral–host cell fusion or viral
entry into host cells.
Third-generation microbicides include HIV replication and
entry inhibitors.9 In contrast to earlier generations, they are not
effective against other sexually transmittedpathogens andarenot
contraceptive. The most advanced compounds include ARV
medications such as a nucleotide reverse transcriptase inhibitor
(NtRTI) (tenofovir; Gilead) and two non-nucleoside reverse
transcriptase inhibitors (NNRTI) (dapivirine (Tibotec/Virco) and
UC781). These products formulated as vaginal gels are presently
in the early phases of clinical investigation.36–38 The NNRTI MIV-
150 suspended in Carraguard1 gel base (PC-815; Population
Council) is in advanced pre-clinical testing. Third-generation
microbicides could also inhibit HIV infection by interfering with
the binding of the virus to cellular receptors.39 Two inhibitors of
the chemokine receptor CCR5 (CMPD167 (Merck) and PSC-
RANTES) have been shown to protect rhesus macaques after
intravaginal challenge with a simian human immunodeﬁciency
virus.40,41 Recently, maraviroc, the CCR5 inhibitor developed by
Pﬁzer, entered the development pipeline as a candidate microbi-
cide. It is suggested that fusion and integrase inhibitors could also
be candidates.
In addition to gel formulations, coitally-independent micro-
bicides are being developed in the form of vaginal rings made of
silicone elastomer, which allow a controlled sustained release of
ARV drugs over a long period of time, eliminating the need to
apply a formulation before each sexual intercourse.42 However,
there is a concern that ARV-based microbicides could lead to
drug resistance if they are used by HIV-positive women unaware
of their HIV status. Therefore, the protocols of clinical trials
testing ARV-based microbicides have been redesigned to evalu-
ate the risk of HIV-positive women developing resistance (e.g.,
the VOICE study – Vaginal and Oral Interventions to Control the
Epidemic).3. Why should we care about the risk of developing resistance
with ARV-based microbicides?
The risk of developing resistance is more elevated with
formulations or vaginal rings containing a single ARV agent
compared with combinations of drugs with different targets in
the viral lifecycle. All classes of ARV-based microbicides could be
formulated alone or in combination. However, FDA regulations
require that microbicides containing more than one active ingredi-
ent showtheclinical superiorityof combinedactiveagentsovereach
individual component before they can be approved.43 This will add
enormously to the cost and duration of product development.
Considerable work has been accomplished in making ARV
therapy accessible to individuals living in low- andmiddle-income
countries, though much remains to be done in order to attain
universal coverage. In resource-poor countries, it is important to
preserve ﬁrst-line treatment regimens because second-line
therapies are rare and expensive.44 First-line regimens, usually
zidovudine (Retrovir), lamivudine (Epivir), and nevirapine (Vir-
amune), costs nearly $240 per year, whereas second-line regimens,
which often include tenofovir (Viread), emtricitabine (Emtriva)
and lopinavir (Kaletra), cost as much as $750 per year. Tenofovir is
a highly desired ARV in these countries because it is safe, requires
relatively limited toxicity monitoring, and is administered once
daily.45 The systemic tenofovir absorption from a 1% vaginal gel
suggests that the development of resistance is plausible.36
However, tenofovir is currently being evaluated in clinical trials
as a gel-basedmicrobicide and a vaginal ring-basedmicrobicide, as
well as an ‘anti-HIV pill’ in pre-exposure prophylaxis (PrEP).46 It
cannot be excluded that, if marketed, an inconsistent use of these
prevention options for long periods of time by populations at high
risk of acquiring HIV could lead to resistance to tenofovir (such as
the high level tenofovir mutation K65R), which could thereby
compromise future use of this highly desired life-saving drug.
Currently, in regions that are the most hard hit by the HIV/AIDS
epidemic, there is insufﬁcient laboratory capacity as well as
personnel and ﬁnancial resources to perform regular HIV viral load
monitoring and detection of resistance mutations.47 The World
Health Organization (WHO) is launching a public health strategy
through the Global HIV Drug Resistance Surveillance Network
(HIVResNet) and national governments, but the global implemen-
tation still needs the support of policymakers and money.48 In
these countries, viral load measurement costs $20 to $50 per test,
which is four-times more than the CD4 cell count test. Therefore,
patients put on ARV therapy are monitored on the basis of clinical
and immunological parameters only, as recommended by the
WHO.49 Clinical and immunological parameters are less reliable
than viral loadmonitoring and detection of resistancemutations to
evaluate therapy failure, leading to unnecessary switches to
second-line regimens in the absence of treatment failure or to
longer administration of a failing treatment regimen.50–52 This
could create the conditions for an accelerated development of HIV
resistance to ARV drugs.53 This situation will be even more
complicated if individuals, at high risk of infection, use micro-
bicides containing ARVs inconsistently and for long periods of time
without knowing their HIV status. Therefore, there should be
laboratory capacity, personnel, and ﬁnancial resources in place to
perform HIV diagnostics and detection of resistance mutations
before introducing ARV-based formulations in resource-poor
countries.
4. Non-ARV- versus ARV-based microbicides
To reach the highest possible number of women, microbicides
should be available over-the-counter, which might not be the case
with ARV-based formulations. In contrast, women will not need to
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to gain access to non-ARV-based microbicides. Therefore, these
products could be made rapidly available over-the-counter to a
large number of women in countries most in need of microbicides.
It has been estimated that a microbicide with even a low
effectiveness, but with a wide distribution could have a substantial
impact against the global HIV epidemic.54 In addition, infections by
other sexually transmitted pathogens, especially those causing
ulcerations to the vaginal mucosa, are important risk factors for
HIV acquisition. Therefore, although HIV is the primary target for
most microbicides, broad-spectrum products that have the ability
to cover additional sexually transmitted pathogens may demon-
strate enhanced protection against HIV.55
The development of safe and effective microbicides has been
delayed by limitations in understanding the mechanism of HIV
transmission, the lack of validated animal models, the lack of
established surrogate markers of safety, and the need to enroll and
follow large cohorts of high-risk participants for several years in
order to demonstrate efﬁcacy. Clinical trial failures with the ﬁrst
candidate microbicides has underscored the urgency of identifying
and validating biomarkers predictive of safety and efﬁcacy.56
Several biomarkers have been proposed for the preclinical
evaluation of candidate microbicides, such as epithelial barrier
disruption,57 efﬁcacy in preventingHIV infection in human cervical
explant tissue cultures,58 and effect of seminal plasma on product
efﬁcacy,59 as well as mucosal inﬂammation and susceptibility to
genital herpes in mice.60 In addition, biomarkers such as
evaluation of induction of inﬂammatory response or loss of host
defence,61 altered vaginal microﬂora,62 and ex vivo assessment of
microbicide efﬁcacy63–65 could give information in early clinical
trials about the safety and likely effectiveness of candidate
microbicides. This would allow a better characterization of
candidate microbicides and the detection of less promising
products before they move to large phase IIB/III clinical trials.
Finally, biomarkers of sexual behavior, such as vaginal exposure to
semen66 and adherence to product use67 could help with
interpretation of study results.
With these new tools in hand, we suggest that the development
of over-the-counter non-ARV-based microbicides should be
reinvigorated. There are now new biomarkers of safety and
efﬁcacy to characterize the other promising ﬁrst- and second-
generation products that are in the pipeline for a more rationale
selection of those that could enter into large and expensive phase
IIB/III clinical trials. Non-ARV-based microbicides may have an
important place in the arsenal of HIV preventive options that are
urgently needed by women, especially those living in low- and
middle-income countries, to control their sexual destiny without
jeopardizing the use of life-saving drugs.
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